Compare Sanofi SA (SNY) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Under Armour Inc Class A — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Under Armour Inc Class A trades at $7.3 (market cap $3.07B). The key difference: Sanofi SA is far larger — about 34.1× Under Armour Inc Class A's market cap, and Sanofi SA pays a 5.5% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| SNY | UAA | |
|---|---|---|
Market Cap | $104.83B | $3.07B |
Sector | Health | Consumer Cyclical |
52-Week High | $52.34 | $8.14 |
52-Week Low | $41.33 | $4.17 |
Enterprise Value | $121.32B | $4.70B |
Dividend Yield | 5.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Under Armour (UAA) trades at $7.37, down 0.81% today, with mixed signals: technicals are bullish on moving averages but RSI suggests overbought conditions. Fundamentally, the company reported a net loss of $201.27M in 2025 with negative margins, though recent quarters showed earnings beats. Cash flow trends are volatile, with 2025 net cash outflow of $361.87M. News highlights include a new Dodge collaboration and upcoming Q1 2027 earnings on August 7, 2026.
The outlook remains challenging due to weak North American sales and margin pressure, but international growth offers some offset. Analyst consensus is cautious with a $5.96 price target below current levels. Key risks include consumer spending softness and high debt. For investors, stabilization in earnings and cost control are critical for a turnaround, though near-term headwinds persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
